Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption
EW•Edwards Lifesciences reported third-quarter sales of $1.72 billion and adjusted EPS of $0.80, beating analyst expectations of $1.68 billion and $0.74. It raised its 2026 sales growth and adjusted EPS guidance after revenue grew 10.5%.
1. Quarterly results
Third-quarter revenue rose 10.5% to $1.72 billion, above the $1.68 billion analyst consensus. Adjusted EPS increased 19% to $0.80, beating the $0.74 consensus; reported EPS was $0.53.
2. Raised outlook
Edwards raised its 2026 sales growth guidance to about 11.5% from 10%-11%, and its TAVR sales growth outlook to 9%-9.5% from 8%-9%. For the fourth quarter, it expects sales of $1.67 billion to $1.75 billion and adjusted EPS of $0.61 to $0.69.
3. Portfolio drivers
Global TAVR sales rose 8%, driven by increased procedure volumes and proactive disease management of severe aortic stenosis. TMTT sales grew 44%, with continued adoption of mitral and tricuspid therapies, including the PASCAL and EVOQUE systems. Manufacturing efficiencies and foreign exchange offset the scaling of newer therapies and improved gross margin.
